APR 12, 2017 9:00 AM PDT

Keynote Presentation - Assessing Risk in Cervical Cancer Screening Management: The Role of HPV Genotyping

Sponsored by: Roche Diagnostics
Speaker
  • Consultant Senior Director, Clinical Research
    Biography
      Catherine Behrens did her PhD research at University of California San Francisco and attended medical school at Stanford University. She completed a Residency in Obstetrics and Gynecology, also at Stanford. Dr. Behrens was in clinical practice for over 20 years and maintains board certification from the American College of Obstetricians and Gynecologists. Dr. Behrens returned to research in the women's health field, initially at Genomic Health and then serving as Senior Director for Clinical Research at Roche Molecular Diagnostics from 2009 until 2015. During her tenure at Roche, Dr. Behrens was the clinical lead for the ATHENA study and a number of additional registrational trials. She currently serves as a consultant in women's health care.

    Abstract

    Screening for cervical cancer represents one of the greatest successes achieved in disease prevention. Cytology has been central to cervical cancer screening programs for over 50 years and has contributed to the 70% decline in rates of cervical cancer in the developed world.3 By the 1990’s, HPV was recognized as a single, necessary cause of cancer of the cervix that was detected in 99.7% of cases of cervical cancer.4 Therefore, tests that detect infection with these high-risk HPV genotypes are now being used increasingly in cervical cancer screening programs.  The 2007 Consensus Guidelines for the Management of Women with Abnormal Cervical Cancer Screening Tests6 recognized the utility of using a combination of cervical cytology, tests for HPV, and genotype-specific HPV testing for women undergoing screening for cervical cancer. These guidelines were subsequently revised and now recommend the combination of cytology and HR HPV testing (cotesting) as the preferred method of screening in women ≥30 years, with HPV 16/18 genotype–specific testing an added option to triage women with negative cytology to colposcopy.7 Most recently, the FDA approved the use of the cobas HPV Test as the first-line primary screen and interim guidance for this screening strategy has been issued and supported by 3 professional societies.

     

    The numerous guideline changes have presented challenges to both laboratories and clinicians. For laboratories, decisions needed to be made regarding which HPV assay to run and how to re-organize resources and workflow to accommodate changing guidelines. For clinicians, choosing the optimal screening strategy and then understanding how to manage the results has become a difficult task.

     

    Today we will try to simplify approaches to cervical cancer screening and management by reviewing the role of HPV genotyping in risk management. Cytology and HPV genotyping results can be used to quantify risks so that we can identify women at the highest risk of having or developing cervical disease and conversely, to identify women at the lowest risk. By utilizing this risk assessment approach, laboratorians and clinicians will better be able to choose the most efficient screening methodology and also more easily manage results that are often confounding and confusing.


    Show Resources
    You May Also Like
    APR 07, 2020 8:00 AM PDT
    C.E. CREDITS
    APR 07, 2020 8:00 AM PDT
    DATE: April 7, 2020 TIME: 8:00am PT, 11:00am ET This webinar sets out to establish why quality control is key to robust, reliable, reproducible science. We will look at best practice criteri...
    JUN 09, 2020 10:00 AM PDT
    C.E. CREDITS
    JUN 09, 2020 10:00 AM PDT
    DATE: June 9, 2020 TIME: 10:00am PT, 1:00pm ET The presentation will first discuss sepsis as a disease and then explain the importance of performing diagnostic tests in the clinical labora...
    FEB 25, 2020 9:00 AM PST
    C.E. CREDITS
    FEB 25, 2020 9:00 AM PST
    Learn about how to generate a small scale CAR-T workflow using ThermoFisher products See detailed characterization tools that can be utilized and applied in a CAR-T workflow...
    MAY 08, 2020 10:00 AM PDT
    C.E. CREDITS
    MAY 08, 2020 10:00 AM PDT
    DATE: May 8, 2020 TIME: 10:00am PT, 11:00am MT, 1:00pm ET The application of next generation sequencing to interrogate immune repertoires and methods in which these highly complex dataset...
    MAR 03, 2020 9:00 AM JST
    C.E. CREDITS
    MAR 03, 2020 9:00 AM JST
    DATE: March 3, 2020 TIME: 9:00am JST A major limitation in the ex vivo expansion of harvested human hematopoietic stem-progenitor cells (HSPCs) is the rapid differentiation of HSPCs at the e...
    MAR 31, 2020 9:00 AM PDT
    C.E. CREDITS
    MAR 31, 2020 9:00 AM PDT
    DATE: March 31, 2020 TIME: 9:00am PT, 12:00pm ET HER2-positive breast cancer is a type of breast cancer caused by over-expression of a protein called human epidermal growth factor receptor 2...
    Loading Comments...
    Show Resources
    Attendees
    • See more